The latest price target for Mainz Biomed (NASDAQ:MYNZ) was reported by HC Wainwright & Co. on November 25, 2024. The analyst firm set a price target for $0.00 expecting MYNZ to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Mainz Biomed (NASDAQ:MYNZ) was provided by HC Wainwright & Co., and Mainz Biomed downgraded their neutral rating.

There is no last upgrade for Mainz Biomed

The last downgrade for Mainz Biomed NV happened on November 25, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Mainz Biomed NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mainz Biomed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mainz Biomed was filed on November 25, 2024 so you should expect the next rating to be made available sometime around November 25, 2025.

While ratings are subjective and will change, the latest Mainz Biomed (MYNZ) rating was a downgraded with a price target of $0.00 to $0.00. The current price Mainz Biomed (MYNZ) is trading at is $6.04, which is out of the analyst’s predicted range.